1 trial changed in the last 30 days: 0 stopped, 0 with notable changes, 1 with a minor change only.
Enrollment closed, study ongoing
Also in this update: Final enrollment: 18 participants (planned 25)
Jonsson Comprehensive Cancer CenterPhase 2 NCT04712851 Registry history of NCT04712851 on ClinicalTrials.gov (opens the registry)
Updated
| Early Phase 1 | 7 | |
| Phase 1 | 17 | |
| Phase 1/2 | 10 | |
| Phase 2 | 34 | |
| Phase 3 | 4 | |
| Phase 4 | 1 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 4 | ||||
| NCT06934239 | A Trial Comparing Screening Mammography With and Without Assistance From Artificial… | Breast Cancer Screening | Recruiting | 2025-11-26 |
| Phase 3 | ||||
| NCT07461948 | Advanced Imaging Techniques for Evaluating the Tumor Immune Microenvironment in… | Glioblastoma | Recruiting | 2026-03-10 |
| NCT07293585 | Vascular Optimized Radiotherapy Tuned to Critical Structures for Erectile Function Using… | Prostate Cancer | Recruiting | 2025-12-19 |
| NCT06448286 | PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve… | Glioblastoma | Not Yet Recruiting | 2026-07-07 |
| NCT03582774 | Multicenter Randomized Trial of 68Ga-PSMA-11 PET/CT Based SRT After Radical Prostatectomy | Recurrent Prostate Carcinoma | Active, Not Recruiting | 2026-05-26 |
| Phase 2 | ||||
| NCT06980077 | Ivonescimab for the Treatment of Thymic Cancer | Thymus Carcinoma | Recruiting | 2026-10-05 |
| NCT07185165 | An Investigational Scan (Flotufolastat F 18 PET/CT) for Detecting Residual or Recurrent… | Prostate Carcinoma | Recruiting | 2026-09-29 |
| NCT07150715 | Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed… | Oligometastatic Prostate Adenocarcinoma | Recruiting | 2026-09-17 |
| NCT03603223 | Pembrolizumab in Treating Participants With Leukoplakia | Erythroleukoplakia | Recruiting | 2026-08-20 |
| NCT07191717 | Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast… | Anatomic Stage I Breast Cancer AJCC v8 | Recruiting | 2026-08-20 |
| NCT06113016 | Prevention of Frailty With Fisetin and Exercise in Breast Cancer Survivors | Anatomic Stage I Breast Cancer American Joint Committee on Cancer (AJCC) v8 | Recruiting | 2026-07-30 |
| NCT04469764 | Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer | Recurrent Endometrial Carcinoma | Recruiting | 2026-07-17 |
| NCT05595499 | Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors | Anatomic Stage I Breast Cancer AJCC v8 | Recruiting | 2026-07-17 |
| NCT06067269 | Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for… | Prostate Adenocarcinoma | Recruiting | 2026-07-17 |
| NCT05775471 | Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical… | Renal Pelvis and Ureter Urothelial Carcinoma | Recruiting | 2026-07-16 |
| NCT06447103 | An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the… | Clear Cell Renal Cell Carcinoma | Recruiting | 2026-06-15 |
| NCT06436612 | Study of Magnetic Resonance Image and Computed Tomography-Guided Stereotactic Body… | Abdominopelvic Sarcomas | Recruiting | 2026-06-05 |
| NCT07323641 | Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non… | Lung Non-Small Cell Carcinoma | Recruiting | 2026-04-20 |
| NCT06288113 | Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant… | Castration-Resistant Prostate Carcinoma | Recruiting | 2026-03-13 |
| NCT06216249 | Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment… | Prostate Carcinoma | Recruiting | 2026-03-10 |
| NCT04553770 | Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of… | Early-stage Breast Cancer | Recruiting | 2025-11-10 |
| NCT04712851 | Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia | Cervical Intraepithelial Neoplasia | Active, Not Recruiting | 2026-10-06 |
| NCT06788938 | Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine… | DLL3-expressing Tumors | Active, Not Recruiting | 2026-09-01 |
| NCT04395079 | Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With… | Metastatic Malignant Female Reproductive System Neoplasm | Active, Not Recruiting | 2026-07-17 |
| NCT04915508 | Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the… | Prostate Adenocarcinoma | Active, Not Recruiting | 2026-07-17 |
Prostate Cancer (32) · Lung Cancer (12) · Breast Cancer (11) · Colorectal Cancer (8) · Glioma (8) · Head & Neck Cancer (8) · Sarcoma (8) · Non-Small Cell Lung Cancer (NSCLC) (7) · Bladder Cancer (5) · Glioblastoma (5)